drugset
drugset / Trial / NCT01340677

A Pharmacokinetic Dose Proportionality Study of Canagliflozin in Healthy Volunteers

NCT01340677 ↗

Phase 1 Completed 24 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CrossoverOpen-label

Summary

The purpose of this study is to evaluate the effect of dose on the pharmacokinetics of canagliflozin in healthy volunteers.

Timeline

Start
2011-05
Primary completion
2011-08
Completion
2011-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject CANAGLIFLOZIN ANHYDROUS Small molecule 50 mg Oral
Subject CANAGLIFLOZIN ANHYDROUS Small molecule 100 mg Oral
Subject CANAGLIFLOZIN ANHYDROUS Small molecule 300 mg Oral

Indications

No indication recorded.